Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CUE
- Price
- 0.79
- Stock movement up
- +0.02 (3.25%)
- Company name
- Cue Biopharma
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 50.11M
- Ent value
- 37.13M
- Price/Sales
- 5.26
- Price/Book
- 1.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -10.55%
- 1 year return
- -55.06%
- 3 year return
- -48.88%
- 5 year return
- -45.60%
- 10 year return
- -
Last updated: 2025-04-14
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CUE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.26 |
| Price to Book | 1.98 |
| EV to Sales | 3.90 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.35M |
| EPS (TTM) | -0.87 |
| FCF per share (TTM) | -0.75 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.53M |
| Gross profit (TTM) | -1.70M |
| Operating income (TTM) | -45.54M |
| Net income (TTM) | -44.61M |
| EPS (TTM) | -0.87 |
| EPS (1y forward) | -0.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -17.81% |
| Operating margin (TTM) | -477.77% |
| Profit margin (TTM) | -468.02% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.42M |
| Net receivables | 3.15M |
| Total current assets | 37.26M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 44.81M |
| Accounts payable | 6.47M |
| Short/Current long term debt | 9.51M |
| Total current liabilities | 16.79M |
| Total liabilities | 19.44M |
| Shareholder's equity | 25.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -38.26M |
| Capital expenditures (TTM) | 66.00K |
| Free cash flow (TTM) | -38.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -175.87% |
| Return on Assets | -99.56% |
| Return on Invested Capital | -138.44% |
| Cash Return on Invested Capital | -118.93% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.79 |
| Daily high | 0.83 |
| Daily low | 0.74 |
| Daily Volume | 343K |
| All-time high | 30.73 |
| 1y analyst estimate | 3.60 |
| Beta | 1.80 |
| EPS (TTM) | -0.87 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Jun 2025 |
Downside potential
Loading...
Downside potential data
| CUE | S&P500 | |
| Current price drop from All-time high | -97.43% | -12.04% |
| Highest price drop | -98.52% | -56.47% |
| Date of highest drop | 26 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -65.10% | -11.07% |
| Avg time to new high | 63 days | 12 days |
| Max time to new high | 1224 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
50.11M
Marketcap category
Small-cap
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Employees
53
Website
Investor relations
-
SEC filings
CEO
Daniel R. Passeri
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page